Roche's decision to stop development of two huntingtin-lowering programmes is disappointing, but the story doesn't end there. Years of research have answered some key questions, raised many new ones, and will inform the next generation of HD trials. Read about it here: en.hdbuzz.net/looking-back...

July was a hard month for Huntington’s disease research, with Roche ending two HD programs. But the month also brought promising new tools to visualize and track huntingtin, and important studies on eating and self-awareness in HD. Read the full recap: en.hdbuzz.net/july-2026-th...

Published ANX005 trial results show the drug is safe, works as designed and may help people with Huntington’s disease - so what’s the holdup? en.hdbuzz.net/putting-it-i...

Scientists screened over a trillion tiny ring-shaped protein fragments to find ones that can grab onto the huntingtin. They captured huntingtin straight out of cells and discovered it’s almost always paired with a partner called HAP40. en.hdbuzz.net/catching-a-g...

A new study suggests that reduced awareness of symptoms, known as anosognosia, may appear even in the earliest stages of HD. The findings highlight that understanding symptom progression requires more than one perspective. en.hdbuzz.net/mirror-mirro...

Skyhawk Therapeutics have received the regulatory approval needed to broaden its FALCON-HD trial to include the United States, Canada, and the UK. The expanded trial will enroll up to 400 more people with Stage 2 and early Stage 3 HD across more than 40 sites worldwide.

Roche announced it is stopping development of two of its huntingtin-lowering ASO drugs, tominersen and RG6496. This marks a disappointing end to an important chapter in HD clinical research. en.hdbuzz.net/roche-ends-t...

For the past 20 years, PET tracers have been a game-changer for Alzheimer’s disease, making it possible to see amyloid plaques in the brain without invasive procedures. So what about Huntington’s? en.hdbuzz.net/are-we-final...

New 12-month data from Skyhawk’s SKY-0515 is in and all four measures that make up the cUHDRS are at or above baseline, beating expected natural decline. Plus, a first look at expanding US trial sites. en.hdbuzz.net/skyhawk-shar...

From the clinic, we heard from uniQure about their recent FDA meeting, a stem cell trial dosed its first participant, and Skyhawk shared data on SKY-0515. In the lab, the science of slowing HD at the DNA level keeps building. en.hdbuzz.net/june-2026-th...

PROTACs act like a precision pruning tool, trimming away toxic huntingtin protein while leaving the healthy form intact. In cells and HD mice, this targeted clean-up improved health and slowed disease features. en.hdbuzz.net/precision-pr...

Australia just made history by banning life insurers from using genetic testing against you. But for HD families in other countries, the laws meant to protect haven’t kept pace with the science. en.hdbuzz.net/your-dna-sho...

REGEN4HD, a new study testing whether transplanting neural stem cells is safe as a potential treatment for HD, has dosed their first participant. Read the full article on our website for more information. en.hdbuzz.net/first-partic...

Huntington’s disease affects more than movement: it also has a major impact on mental health. Researchers explore why psychological care matters and how it needs to be adapted across each stage of HD. en.hdbuzz.net/evolving-nee...

Your body assembles DNA like a team of workers who set and bond a pattern of tiles. A recent study shows that one special assistant might slow somatic CAG expansion and delaying HD onset. en.hdbuzz.net/sealing-the-...

In 2025, you helped us reach 329,000 people with independent, unbiased HD research news. Our 2025 Annual Report is here. Take a look at what we built together, and consider helping us keep going. en.hdbuzz.net/hdbuzz-2025-...

One year into treatment, SKY-0515 continues to lower huntingtin levels and shows encouraging trends in HD signs and symptoms. A larger clinical trial is now enrolling and will help determine whether SKY-0515 can truly slow disease progression in Huntington's disease. en.hdbuzz.net/skyhawk-repo...

May 2026: 2 year data from the votoplam trial suggests disease progression may slow; AMT-130 heads to the UK for regulatory review; pigs reveal immune cells invading the HD brain; and new science zooms in on toxic huntingtin fragments. en.hdbuzz.net/may-2026-thi...

Recently a paper was published where scientists targeted a small, harmful piece of the huntingtin message (HTT1a) in HD mice. This reduced toxic protein clumps and delayed genetic changes, more than targeting full length HTT. Full article: en.hdbuzz.net/fixing-the-r...

A recent study suggests that strengthening the brain’s own clean-up system could slow Huntington’s disease. en.hdbuzz.net/tagging-the-...

After the EMA recommended refusing approval for pridopidine, Prilenia quietly withdrew its European application in November 2025. Here’s what happened, and why you’re only hearing about it now. Full article: en.hdbuzz.net/prilenias-ap...

A recent study in pigs suggests the HD brain could be under attack from the body’s own immune system. The results reveal that invading cytotoxic T cells might contribute to neurodegeneration in HD, suggesting a new therapeutic pathway. en.hdbuzz.net/intruders-in...

What does “good care” look like in Huntington’s Disease? A new Dutch study asked familial and professional caregivers, and uncovered how differently it’s experienced in practice. en.hdbuzz.net/the-great-ca...

The U.S. regulatory path for AMT-130 remains complex, but uniQure has announced plans to seek approval for its Huntington’s disease gene therapy in the UK. Full Article: en.hdbuzz.net/a-second-pat...

PTC Therapeutics has shared 2-year data on votoplam, a once-daily HTT-lowering pill. In Stage 2 participants, results suggest up to 52% slowing of disease progression. Let's go through what the data show, what’s still unclear, and how the Phase 3 trial is taking shape. en.hdbuzz.net/two-years-in...

April 2026 showed us a toxic HTT fragment is center stage in mouse research, CRISPR is showing promise in mouse studies, AI and wearables move closer to the clinic, and 2 studies shine a light on the weight carried by HD caregivers. Full Article: en.hdbuzz.net/april-2026-t...

To kick off Clinic Week during our Fund the Buzz spring fundraising campaign, we're publishing a piece that's been on a lot of people's minds lately: what is a TFC score, and why does it matter so much for the INVEST-HD trial? Full article: en.hdbuzz.net/the-number-o...

Apathy in HD isn’t just “not caring.” It can affect relationships, routines, and emotional connection. A small study of caregivers reveals the heavy toll of apathy and the value of safe spaces to share experiences. en.hdbuzz.net/dancing-with...

HDBuzz is launching Fund the Buzz, our spring fundraising campaign! en.hdbuzz.net/fund-the-buz...

A new study puts “self-switching” genetic scissors to work at the root of Huntington’s disease. In mice, this approach was able to step in after symptoms had already begun, offering a glimpse at what future treatments might look like. en.hdbuzz.net/cutting-to-t...